Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore's HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased that HealthTab, the Company's leading pharmacy-based platform for testing and health data management, has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

"In the wake of the pandemic, it's clear that the community pharmacy needs to play a bigger role in delivering more access to healthcare services, especially chronic disease screening and management," said Hector Bremner, CEO of Avricore Health. "We are honoured to have been selected for this important project and look forward to working with pharmacist as they support patients with this vital service."

The feasibility study seeks deeper insights and ways to build off the successful delivery of over 930,000 blood pressure checks in just over a year through approximately 6000 pharmacies as part of NHS initiative to support risk identification and prevention of cardiovascular disease.

That initiative allowed those with high blood pressure to be identified and referred onward for management. This is critical at this time for such services, as it is estimated that there are over 5 million people with undiagnosed hypertension in the UK today.

Given that significant need, NHS England recently announced £645 million to support increasing access to primary care, including expanding clinical pharmacy as an essential part of recovering the system's ability to deliver timely service. Pharmacy proved during the COVID-19 pandemic it can offer people easy access to health services in the heart of their communities, and with a high-quality screening and health data management tool like HealthTab, they will be able to deliver the same vital support for chronic diseases.

The collaborative, with support of the pharmaceutical industry, will begin the study with five locations throughout London and as the program establishes itself will begin to expand the program to more locations.

The collaborative leading the feasibility study include:

Barts Heart Centre – Is at the forefront of new treatments for heart disease and is proud that its patients have some of the best clinical outcomes in the country. Barts Heart Centre is based at St Bartholomew's Hospital in the City of London, However, cardiac services are also provided at Newham, The Royal London and Whipps Cross hospitals. It treats patients from across the UK for a wide range of complex conditions including coronary heart disease, arrhythmias, heart failure and many other cardiac problems.

HEART UK - The UK's only cholesterol charity, providing support, information and influencing services for families and health professionals. Their vision is to prevent early disease and deaths from cholesterol and other blood fat (lipid) conditions in the UK and aim for people to know and understand their cholesterol and other blood fat (lipid) levels and take appropriate action.

About HealthTab

HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues.

With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

To find a location near you, please visit: healthtab.com/locations .

HealthTab Market Fast Facts

  • Point-of-Care Testing Market to reach $50.6 Billion USD in 2025 ( Source )
  • Glucose monitoring (diabetes related) to make up the largest growth within the sector. ( Source )
  • Nearly 13.6 Million Canadians expected to diabetic or prediabetic by 2030, with many undiagnosed ( Source )
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ( Source )
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. ( Source )
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact:

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements.

In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release.

Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AVCR:CA
The Conversation (0)
Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health Corporate Update - Company Demonstrates Strong Growth

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.

"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

HealthTab Signs Reseller Agreement With Abbott to Support UK Expansion

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a reseller agreement between HealthTab™ Inc. and Abbott Rapid Dx UK & Ireland.

This agreement provides a foundation for HealthTab to purchase and distribute the Afinion™ 2 and associated tests for diabetes and heart disease screening in community pharmacies in the UK.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HealthTab to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

HealthTab to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce its agreement with Ascensia Diabetes Care, a global diabetes care company, to integrate their blood glucose monitoring (BGM) systems, marketed as CONTOUR ® NEXT GEN and CONTOUR ® NEXT ONE, with Avricore's pharmacy-based point-of-care testing (POCT) platform, HealthTab. Ascensia Diabetes Care is a subsidiary of PHC Holdings Corporation (TSE 6523).

The partnership's objective is to support patients and pharmacists in Canada in better managing diabetes by linking the daily blood glucose testing results and pattern history data collected via the CONTOUR ® NEXT GEN or CONTOUR ® NEXT ONE meter the patient uses to the patient's HealthTab account. The partnership also seeks to support utilization of each technology by opening discussions related to collaborative communications to ensure patients and pharmacists are able to take advantage of what these data insights offer.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Syntheia Rings the Opening Bell on the Canadian Securities Exchange

Syntheia Rings the Opening Bell on the Canadian Securities Exchange

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, is pleased to announce that the Company's leadership team rang the bell to open the market in collaboration with the Canadian Securities Exchange to celebrate its successful listing under the symbol "SYAI".

" We look forward to great success through our partnership with the CSE as we commercially launch our conversational AI to the market. On behalf of the Company, I would like to thank everyone who has made this milestone happen, " commented Tony Di Benedetto, Chief Executive Officer at Syntheia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Provaris Energy

Notice of Initial Substantial Holder - Regal Funds Management Pty Ltd

Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder.


Keep reading...Show less
Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative SaaS platform, designed to transform how businesses manage inbound telephone calls is set to launch in January of 2025. Leveraging advanced Natural Language Processing (NLP), Syntheia's virtual assistants enhance communication and efficiency targeting small and medium businesses in this large global marketplace.

" Our mission is to eliminate as many inefficiencies as we can with managing inbound calls that small to medium-sized businesses face utilizing the power of AI" said Tony Di Benedetto, CEO of Syntheia. "With AI-driven virtual assistants, we provide these businesses with tools to improve customer satisfaction while reducing operational costs. We are gearing up now for commercial launch in January of 2025, less than 8 weeks away."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Canadian Securities Exchange Reports October 2024 Performance Figures

Canadian Securities Exchange Reports October 2024 Performance Figures

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2024.

October 2024 Operating Statistics

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

Quarterly Activities Report and Appendix 4C - 30 Sept 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following Quarterly Activities Report and Appendix 4C for the quarter ending 30th September 2024 together with an Operational Update.

Keep reading...Show less

Latest Press Releases

Related News

×